Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Trichogram Hair and Scalp Feature Extraction and Analysis Using Image Processing
"TRICHOASSIST" is a system that analyzes hair and scalp images to help diagnose scalp diseases.
research Trichoscopy in Hair Disorders in Darker Skin: An Approach to Diagnosis
Trichoscopy is useful for diagnosing hair and scalp disorders in people with darker skin.
research Evaluation of the Safety and Effectiveness of Intradermal Administration of QR678 Neo Hair Growth Factor Formulation: A Phase-IV, Open-Label, Single-Arm Multi-Ethnicity Clinical Trial
QR678 Neo® is a safe and effective treatment for hair loss in men and women.
research Vellus Hairs in the Frontal Scalp in Early Female Pattern Hair Loss
More vellus hairs in frontal scalp indicate early female pattern hair loss.
research Efficacy and Safety of Topical KX-826 in Male Subjects with Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study
KX-826 is safe and effectively increases hair count in men with hair loss.
Community Join
5 / 380 resultscommunity Brave soldier leading the army
User saw new hair growth after 2 months of treatment. Others shared similar experiences and joked about hair soldiers reclaiming lost territory.
community 4 Year Update (27M)(Fin+Min+Micro-needling)
EDHARRINGTON's journey to regrow his hair using finasteride, topical minoxidil, and micro-needling treatments over 4 years, with others commenting their support and admiration for his results.
community latanoprost, minoxidil and biotin 3/20/23 vs 5/21/23 same spot
Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.
community pyrilutamide phase 2 results right here, thanks to user Glaringbooch
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.